Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.
Press releases published on April 3, 2025
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 3, 2025
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior …
aTyr Pharma to Participate in April Investor Conferences
GlobeNewswire
·
April 3, 2025
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that …
March Commercial Chapter 11s Increase 20 Percent from Previous Year
GlobeNewswire
·
April 3, 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Commercial chapter 11 bankruptcy filings increased 20 percent in March 2025, with filings climbing to 733 from the 611 filings registered in March 2024, according to data provided by Epiq AACER, the leading …
American Rebel Holdings, Inc. (NASDAQ: AREB) Invites Patriotic Investors, Fans, and Beer Enthusiasts to Celebrate Freedom with a New Video Release Highlighting the American Rebel Story
GlobeNewswire
·
April 3, 2025
Watch the American Rebel Story and learn about America’s Next Great Company as told by CEO Andy Ross Nashville, TN, April 03, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB), the creator of American Rebel Beer and champion of …
electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times
GlobeNewswire
·
April 3, 2025
ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” …
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
GlobeNewswire
·
April 3, 2025
KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation …
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
GlobeNewswire
·
April 3, 2025
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally TMJ causes pain and stiffness in the jaw, making it …
SINTX Technologies Announces Strategic Changes to Board of Directors
GlobeNewswire
·
April 3, 2025
Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company focused on medical device applications, today announced changes to …
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
GlobeNewswire
·
April 3, 2025
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
Genius Group Blocked from Raising Funds and Buying Bitcoin by New York Court
GlobeNewswire
·
April 3, 2025
SINGAPORE, April 03, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced that it is being forced to sell its Bitcoin Treasury after …
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
GlobeNewswire
·
April 3, 2025
MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
GlobeNewswire
·
April 3, 2025
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed …
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire
·
April 3, 2025
NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the …
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
GlobeNewswire
·
April 3, 2025
MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatric Designation granted MNV-201 is also being studied in a Phase Ib for low-risk …
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
GlobeNewswire
·
April 3, 2025
Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and strategic incumbrances, and sets a …
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
GlobeNewswire
·
April 3, 2025
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified …
Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
GlobeNewswire
·
April 3, 2025
NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced data from a poster presentation …
Axonius Appoints David Walters as Chief Revenue Officer
GlobeNewswire
·
April 3, 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Axonius, the leader in cyber asset management that delivers visibility and actionability across all digital assets, today announced the appointment of David Walters as Chief Revenue Officer (CRO). Walters brings …
Lianhe Sowell International Group Ltd Announces Pricing of Initial Public Offering
GlobeNewswire
·
April 3, 2025
Shenzhen, China, April 03, 2025 (GLOBE NEWSWIRE) -- Lianhe Sowell International Group Ltd (the “Company”), a provider of machine vision products and solutions applied in a wide range of businesses across industries in China, today announced the pricing of …
Breaking News: Early Clinical Trial on Plant-Based Finasteride Alternative Shows Exciting Results Amid Growing Concerns Over Drug Side Effects
GlobeNewswire
·
April 3, 2025
CLEVELAND, April 03, 2025 (GLOBE NEWSWIRE) -- The hair loss industry is at a tipping point. A recent Wall Street Journal exposé has reignited concerns about the severe and long-term side effects of finasteride, the FDA-approved drug for male pattern …